First-of-Kind Trial Studies OS in Post-allograft –Relapsed AML

The research, published inJAMA Oncology, evaluates  survival outcomes of a second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion.

Source: CancerNetwork - October 10, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news